Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry.
Patient-reported outcomes
Real-world evidence
Registry
Rheumatoid arthritis
Upadacitinib
Journal
Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543
Informations de publication
Date de publication:
12 Feb 2024
12 Feb 2024
Historique:
received:
09
08
2023
accepted:
12
01
2024
medline:
12
2
2024
pubmed:
12
2
2024
entrez:
12
2
2024
Statut:
aheadofprint
Résumé
Data assessing longer-term real-world effectiveness and treatment patterns with upadacitinib (UPA), a Janus kinase inhibitor, in rheumatoid arthritis (RA) are lacking. We assessed improvement in clinical and patient-reported outcomes and treatment patterns for up to 12 months among adult patients with RA initiating UPA. Data were collected from the CorEvitas Patients treated with UPA (6-month cohort, N = 469; 12-month cohort, N = 263) had statistically significant improvements (p < 0.001) in mean CDAI, tender/swollen joint counts, pain, and fatigue at follow-up. At 12 months, 46.0% achieved MCID in CDAI and 40.0% achieved low disease activity/remission. Overall, 43.0% discontinued UPA at 12 months; of those receiving combination treatment (N = 90) with conventional therapies and UPA, 42.2% (N = 38) discontinued conventional therapy. Findings were similar in the 6-month cohort and among subgroups. Changes from baseline and proportions of patients achieving MCID or clinical outcomes tended to be numerically lower among patients with TNFi experience and numerically higher among those receiving UPA as first-line therapy. UPA initiation was associated with improvements in clinical and patient-reported outcomes, with meaningful clinical improvements regardless of prior TNFi experience, line of therapy, or concomitant use of conventional therapies. Further research is needed to better understand sustained response of UPA over longer treatment periods.
Identifiants
pubmed: 38345715
doi: 10.1007/s40744-024-00639-4
pii: 10.1007/s40744-024-00639-4
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Coates LC, FitzGerald O, Helliwell PS, Paul C. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same? Semin Arthritis Rheum. 2016;46(3):291–304. https://doi.org/10.1016/j.semarthrit.2016.05.012 .
doi: 10.1016/j.semarthrit.2016.05.012
pubmed: 27388027
Geijer M, Alenius GM, Andre L, et al. Health-related quality of life in early psoriatic arthritis compared with early rheumatoid arthritis and a general population. Semin Arthritis Rheum. 2021;51(1):246–52. https://doi.org/10.1016/j.semarthrit.2020.10.010 .
doi: 10.1016/j.semarthrit.2020.10.010
pubmed: 33385865
Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108–23. https://doi.org/10.1002/art.41752 .
doi: 10.1002/art.41752
pubmed: 34101376
Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18. https://doi.org/10.1136/ard-2022-223356 .
doi: 10.1136/ard-2022-223356
pubmed: 36357155
Lin YJ, Anzaghe M, Schulke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020. https://doi.org/10.3390/cells9040880 .
doi: 10.3390/cells9040880
pubmed: 33375719
pmcid: 7823273
Bergman MJ, Kivitz AJ, Pappas DA, et al. Clinical utility and cost savings in predicting inadequate response to Anti-TNF therapies in rheumatoid arthritis. Rheumatol Ther. 2020;7(4):775–92. https://doi.org/10.1007/s40744-020-00226-3 .
doi: 10.1007/s40744-020-00226-3
pubmed: 32797404
pmcid: 7695768
Ertenli AI, Kalyoncu U, Karadag O, et al. Trends in the choice of first biologic and targeted synthetic DMARD in rheumatoid arthritis patients: 20-years journey of HURBIO real-life registry [abstract]. Ann Rheum Dis. 2021;80:1124.
doi: 10.1136/annrheumdis-2021-eular.693
Aaltonen KJ, Ylikyla S, TuulikkiJoensuu J, et al. Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Rheumatol (Oxf). 2017;56(5):725–35. https://doi.org/10.1093/rheumatology/kew467 .
doi: 10.1093/rheumatology/kew467
Arnell C, Bergman M, Basu D, et al. Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility. J Manag Care Spec Pharm. 2021;27(12):1734–42. https://doi.org/10.18553/jmcp.2021.21120 .
doi: 10.18553/jmcp.2021.21120
pubmed: 34669487
Radawski C, Genovese MC, Hauber B, et al. Patient perceptions of unmet medical need in rheumatoid arthritis: a cross-sectional survey in the USA. Rheumatol Ther. 2019;6(3):461–71. https://doi.org/10.1007/s40744-019-00168-5 .
doi: 10.1007/s40744-019-00168-5
pubmed: 31385264
pmcid: 6702617
AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an oral JAK inhibitor for the treatment of moderate to severe rheumatoid arthritis [press release]. AbbVie, Inc., 16 August 2019. 2019.
AbbVie Inc. Rinvoq
AbbVie receives European Commission approval of RINVOQ™ (upadacitinib) for the treatment of adults with moderate to severe active rheumatoid arthritis [press release]. December 18, 2019. 2019.
Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513–24. https://doi.org/10.1016/S0140-6736(18)31116-4 .
doi: 10.1016/S0140-6736(18)31116-4
pubmed: 29908670
Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503–12. https://doi.org/10.1016/S0140-6736(18)31115-2 .
doi: 10.1016/S0140-6736(18)31115-2
pubmed: 29908669
Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788–800. https://doi.org/10.1002/art.41032 .
doi: 10.1002/art.41032
pubmed: 31287230
Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383(16):1511–21. https://doi.org/10.1056/NEJMoa2008250 .
doi: 10.1056/NEJMoa2008250
pubmed: 33053283
Curtis JR, Chen L, Danila MI, et al. Routine use of quantitative disease activity measurements among US rheumatologists: implications for treat-to-target management strategies in rheumatoid arthritis. J Rheumatol. 2018;45(1):40–4. https://doi.org/10.3899/jrheum.170548 .
doi: 10.3899/jrheum.170548
pubmed: 29142029
Pappas DA, Tundia N, Shan Y, Litman HJ, Kremer J. Unmet treat-to-target goals with available targeted immunomodulators in the management of rheumatoid arthritis: real world evidence from the Corrona registry [abstract]. Arthritis Rheumatol. 2018;70(Suppl 9).
Mease P, Strand V, Gladman D. Functional impairment measurement in psoriatic arthritis: importance and challenges. Semin Arthritis Rheum. 2018;48(3):436–48. https://doi.org/10.1016/j.semarthrit.2018.05.010 .
doi: 10.1016/j.semarthrit.2018.05.010
pubmed: 30029795
Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004;8(4):283–91. https://doi.org/10.1016/j.ejpain.2003.09.004 .
doi: 10.1016/j.ejpain.2003.09.004
pubmed: 15207508
Strand V, Boers M, Idzerda L, et al. It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol. 2011;38(8):1720–7. https://doi.org/10.3899/jrheum.110392 .
Kitchen H, Hansen BB, Abetz L, Hojbjerre L, Strandberg-Larsen M. Patient-reported outcome measures for rheumatoid arthritis: minimal important differences review. Arthritis Rheum. 2013;65(Suppl 10):Abstract 2268.
Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1986;26(5):404–13.
Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303–11. https://doi.org/10.1016/S0140-6736(19)30419-2 .
doi: 10.1016/S0140-6736(19)30419-2
pubmed: 31130260
Movahedi M, Cesta A, Li X, et al. Physician- and patient-reported effectiveness are similar for tofacitinib and TNFi in rheumatoid arthritis: data from a rheumatoid arthritis registry. J Rheumatol. 2022;49(5):447–53. https://doi.org/10.3899/jrheum.211066 .
doi: 10.3899/jrheum.211066
pubmed: 35169051
Finckh A, Tellenbach C, Herzog L, et al. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open. 2020. https://doi.org/10.1136/rmdopen-2020-001174 .
doi: 10.1136/rmdopen-2020-001174
pubmed: 32385143
pmcid: 7299517